HLA haploidentical stem cell transplantation using myeloablative regimen including ATG
Phase 1
- Conditions
- hematologic malignancies
- Registration Number
- JPRN-UMIN000004904
- Lead Sponsor
- Hyogo College of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Allergy for the agents used in conditioning or GVHD prophylaxis 2) Patients who are considered as inappropriate with other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method survival on day 100
- Secondary Outcome Measures
Name Time Method acute GVHD, complications, relapse within three months